Qtron Investments LLC Makes New Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Qtron Investments LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,045 shares of the company's stock, valued at approximately $845,000.

Other institutional investors have also modified their holdings of the company. M&T Bank Corp raised its holdings in IDEXX Laboratories by 1.6% during the 3rd quarter. M&T Bank Corp now owns 5,693 shares of the company's stock worth $2,876,000 after buying an additional 92 shares during the period. Sanctuary Advisors LLC increased its position in IDEXX Laboratories by 20.4% in the 3rd quarter. Sanctuary Advisors LLC now owns 3,288 shares of the company's stock worth $1,661,000 after purchasing an additional 558 shares during the last quarter. Tidal Investments LLC raised its position in IDEXX Laboratories by 7.6% during the third quarter. Tidal Investments LLC now owns 6,310 shares of the company's stock valued at $3,188,000 after acquiring an additional 444 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of IDEXX Laboratories by 2.5% in the third quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company's stock worth $675,259,000 after buying an additional 34,305 shares during the last quarter. Finally, American Trust acquired a new stake in IDEXX Laboratories during the third quarter worth about $757,000. Institutional investors and hedge funds own 87.84% of the company's stock.

IDEXX Laboratories Trading Up 2.3 %

Shares of NASDAQ IDXX traded up $9.34 during mid-day trading on Friday, hitting $411.72. The company's stock had a trading volume of 965,481 shares, compared to its average volume of 622,945. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The company's fifty day simple moving average is $423.41 and its 200-day simple moving average is $431.80. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The stock has a market cap of $33.37 billion, a price-to-earnings ratio of 38.59, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IDXX shares. Morgan Stanley lowered their price target on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, April 12th. Barclays boosted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Piper Sandler lifted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Finally, Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $523.75.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.